Posted by Michael Wonder on 28 Oct 2020
Leo Pharma is withdrawing the drug Picato (ingenol mebutate), used to treat skin lesions, due to the potential increased risk of skin cancer
27 October 2020 - At Health Canada's request, Leo Pharma is withdrawing Picato from the Canadian market.
This follows a safety review by the Department, which concluded that use of Picato may be associated with an increased risk of non-melanoma skin cancer, and that the benefits of using Picato no longer outweigh its potential risks.
